{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:46:23Z","timestamp":1793778383174,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jhep.2022.07.010","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T11:50:15Z","timestamp":1658317815000},"page":"1287-1298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB"],"prefix":"10.1016","volume":"77","author":[{"given":"Man-Fung","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Locarnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Huey","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone I.","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sievert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Given","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schluep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Biermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Kalmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Beumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"De Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Cloherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Ka-Ho Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching Lung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Gish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhep.2022.07.010_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2022.07.010_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/v9050095","article-title":"Interplay between the hepatitis B virus and innate immunity: from an understanding to the development of therapeutic concepts","volume":"9","author":"Faure-Dupuy","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2022.07.010_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir Res"},{"issue":"8","key":"10.1016\/j.jhep.2022.07.010_bib4","doi-asserted-by":"crossref","first-page":"a021428","DOI":"10.1101\/cshperspect.a021428","article-title":"Immune response in hepatitis B virus infection","volume":"5","author":"Tan","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jhep.2022.07.010_bib5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2022.07.010_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.07.010_bib7","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.010_bib8","article-title":"Association between seroclearance of Hepatitis B surface antigen and long-term clinical outcomes of patients with chronic Hepatitis B Virus infection: systematic review and meta-analysis","author":"Anderson","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.07.010_bib9","article-title":"Hepatitis B virus infection","volume":"7","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.jhep.2022.07.010_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2022.07.010_bib11","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0168-8278(18)30255-1","article-title":"Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic heptitis B virus infections","volume":"68","author":"Wooddell","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.010_bib12","article-title":"Single-ascending dose (SAD) pharmacokinetics of hepatitis B virus (HBV)- specific JNJ-73763989 in non-Japanese and Japanese healthy volunteers (HV)","author":"Kakuda","year":"2020","journal-title":"Clin Pharm Workshop"},{"key":"10.1016\/j.jhep.2022.07.010_bib13","series-title":"EASL the digital international liver congress, 27-29 August","article-title":"Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: interim week 24 data","author":"Janssen","year":"2020"},{"issue":"5","key":"10.1016\/j.jhep.2022.07.010_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02439-19","article-title":"Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379","volume":"64","author":"Berke","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jhep.2022.07.010_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a Phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.07.010_bib16","unstructured":"Hoffman-La Roche. Elecsys\u00ae HBsAg II. (https:\/\/diagnostics.roche.com\/global\/en\/products\/params\/elecsys-anti-hbs-ii.html). Last accessed: 4th May\u00a02021."},{"key":"10.1016\/j.jhep.2022.07.010_bib17","unstructured":"Diasorin. Liaison\u00ae. (https:\/\/www.diasorin.com\/sites\/default\/files\/allegati_prodotti\/ese_liaison_xl_hepatitis_ab_low.pdf). Last accessed: 4th May\u00a02021."},{"key":"10.1016\/j.jhep.2022.07.010_bib18","unstructured":"Fujirebio. Lumipulse. (https:\/\/www.fujirebio.com\/en\/products-solutions\/lumipulser-g1200). Last accessed: 4th May\u00a02021."},{"key":"10.1016\/j.jhep.2022.07.010_bib19","unstructured":"Abbott. m2000. (https:\/\/www.molecular.abbott\/int\/en\/products\/instrumentation\/m2000-realtime-system). Last accessed: 4th May\u00a02021."},{"key":"10.1016\/j.jhep.2022.07.010_bib20","unstructured":"Hoffman-La Roche. Cobas\u00ae HBV DNA test. (https:\/\/diagnostics.roche.com\/global\/en\/products\/params\/cobas-hbv-test.html). Last accessed: 4th May\u00a02021."},{"key":"10.1016\/j.jhep.2022.07.010_bib21","series-title":"AASLD the liver meeting, 13-16 November","article-title":"HBV pgRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued NrtI treatment in patients with HBeAg positive chronic hepatitis B virus infection: findings from a phase 2 open-label study","author":"Yuen","year":"2020"},{"key":"10.1016\/j.jhep.2022.07.010_bib22","series-title":"Presented at EASL the digital international liver congress\u2122 27-29 August","article-title":"Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: interim week 24 data","author":"Janssen","year":"2020"},{"issue":"21","key":"10.1016\/j.jhep.2022.07.010_bib23","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.jhep.2022.07.010_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41598-017-00111-0","article-title":"Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jhep.2022.07.010_bib25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed ciruclar DNA transcriptional activity in chronic hepatits B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2022.07.010_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA interference therapy with ARC-520 results in prolonged HBsAg response in patients with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"issue":"409","key":"10.1016\/j.jhep.2022.07.010_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.jhep.2022.07.010_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135348","article-title":"Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease","volume":"5","author":"Wooddell","year":"2020","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.jhep.2022.07.010_bib29","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2022.07.010_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"Lancet Gasteroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.010_bib31","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2009.05.044","article-title":"Stem cells and liver regeneration","volume":"137","author":"Duncan","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822029415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822029415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:47:35Z","timestamp":1759175255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822029415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0168827822029415"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.07.010","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}